Addiction medicine

Virtue Recovery Opens State-of-the-Art Detox Facility in Houston, TX

Retrieved on: 
Monday, April 8, 2024
Aftercare, Hope, Empowerment, Growth, Environment, Rehabilitation, Addiction medicine, Hospital

HOUSTON, April 8, 2024 /PRNewswire-PRWeb/ -- "This new facility in Houston is a testament to Virtue Recovery Center's dedication to leading-edge addiction treatment and its belief in the transformative power of a comprehensive, patient-centered approach. Incorporating evidence-based and holistic therapies ensures that individuals receive the most effective and personalized care possible." Stated Michael Banis (Chief Development Officer) at Virtue Recovery in Houston, TX. "Our expansion into Houston, TX, is a light of hope, offering an innovative and deeply compassionate path to recovery. This move is more than just a geographical expansion; it's a redefinition of what it means to seek and find healing from addiction. It's about ensuring that every individual has access to a recovery process that truly understands and addresses their journey towards healing."

Key Points: 
  • Virtue Recovery Center's latest venture in Houston, TX, introduces a pioneering state-of-the-art detox facility, setting new standards in addiction recovery care.
  • At Virtue Recovery Center, we're not just opening a facility but unveiling a new chapter in addiction recovery.
  • Emphasizing a personalized approach to recovery, Virtue Recovery Center prides itself on developing treatment programs as unique as the individuals they serve.
  • As Virtue Recovery Center unveils its state-of-the-art detox facility in Houston, TX, it stands as a testament to the center's unwavering commitment to advancing addiction recovery.

Battling the opioid epidemic: New research shows access to opioid use disorder treatment in emergency rooms saves lives

Retrieved on: 
Tuesday, March 26, 2024
JAMA, EDS, American Medical Association, Survival, Addiction medicine, AHS, Patient, OUD, Journal, Research, Buprenorphine, Opioid use disorder, Emergency department, Drug, ED, Alameda Health System, Pharmaceutical industry

The research points to emergency rooms as critical gateways for providers to reach and treat patients with opioid use disorder.

Key Points: 
  • The research points to emergency rooms as critical gateways for providers to reach and treat patients with opioid use disorder.
  • Emergency departments are often the lowest-barrier access point for people seeking immediate health care.
  • This research shows that initiation of buprenorphine in the emergency department, combined with linkage to outpatient treatment, saves lives.
  • The Bridge Clinic at AHS is at the forefront of bringing opioid use disorder treatment to patients in Alameda County.

Collaboration with Ophelia Provides Highmark Wholecare Members Collaboration With Access to Opioid Use Disorder Treatment

Retrieved on: 
Wednesday, March 20, 2024
Psychiatry, Addiction medicine, Education, Patient, MAT, OUD, Travel, Buprenorphine, Prescription, Death, Opioid use disorder, Methadone, Drug, CDC, Medicaid, Medicare, Food, Fentanyl, Pharmaceutical industry

Ophelia has been part of Highmark Wholecare parent company Highmark Health's network in Pennsylvania since July 2021, serving 2.9 million commercial members.

Key Points: 
  • Ophelia has been part of Highmark Wholecare parent company Highmark Health's network in Pennsylvania since July 2021, serving 2.9 million commercial members.
  • In addition to treatment deserts and localized provider shortages, people with OUD tend to experience financial hurdles when seeking treatment.
  • "Highmark Wholecare's collaboration with Ophelia is helping course correct this crisis by providing access to comprehensive OUD care that our Medicaid and D-SNP members can receive quickly and safely."
  • "Our expanded collaboration with Highmark Health through Highmark Wholecare members allows us to serve communities that continue to be severely impacted by the opioid epidemic," said Zack Gray , CEO and co-founder at Ophelia.

MCG Releases 28th Edition of Guidelines with New Support for the 2024 Medicare Advantage Final Rule

Retrieved on: 
Tuesday, February 27, 2024
Language, Hospital, Addiction medicine, CMS, MCG, Health, Transport, Medicare Advantage, Citation, Data, ASAM, Ambulatory care, Society, Medicare, Hearst Communications, Health insurance

SEATTLE, Feb. 27, 2024 /PRNewswire-PRWeb/ -- MCG Health, part of the Hearst Health network and an industry leader in technology-enabled evidence-based guidance, announces the release of its 28th edition of the MCG care guidelines. Many new changes to the industry-leading guidelines were made to help payers and providers support compliance with the 2024 Medicare Advantage and Part D Final Rule (CMS-4201-F) which was announced by the Centers for Medicare & Medicaid Services (CMS) in April 2023.

Key Points: 
  • Many new changes to the industry-leading guidelines were made to help payers and providers support compliance with the 2024 Medicare Advantage and Part D Final Rule (CMS-4201-F) which was announced by the Centers for Medicare & Medicaid Services (CMS) in April 2023.
  • - Jon Shreve, President & CEO, MCG Health
    MCG care guidelines are among the most widely used clinical guidelines in the healthcare industry.
  • The updates were designed to help payers and providers support compliance with the 2024 Medicare Advantage and Part D Final Rule (CMS-4201-F).
  • In addition, MCG will hold several educational sessions related to the 28th edition at their annual Client Forum in Phoenix, Arizona (April 22-24).

Anonymous Health Expands Innovative Addiction Care Services to Oregon

Retrieved on: 
Wednesday, February 21, 2024
Fentanyl, MAT, Addiction medicine, Heroin, Cocaine, Interest, Nicotine, Health, Anonymous, Internal medicine, Patient, Senior counsel, Case management, Providence Health & Services, Addiction

PORTLAND, Ore., Feb. 21, 2024 /PRNewswire/ -- Anonymous Health, a pioneer in outpatient teletherapy services, is proud to announce its statewide expansion across Oregon.

Key Points: 
  • PORTLAND, Ore., Feb. 21, 2024 /PRNewswire/ -- Anonymous Health, a pioneer in outpatient teletherapy services, is proud to announce its statewide expansion across Oregon.
  • "We are excited to help address long-standing capacity and access challenges of addiction care in Oregon, including in rural communities," said Medical Director, Dr. Palani Chidambaram.
  • "(1) Dr. Chidambaram is Board certified in Internal Medicine and Addiction Medicine, and he founded and leads the addiction medicine practice at several Providence Health System hospitals in the Portland, Oregon region.
  • Personalized Care and Advanced Technology: Anonymous Health's Approach
    Patients at Anonymous Health receive near-immediate attention from a dedicated Concierge Care Manager.

Caron Treatment Centers Expands Its Neurorestorative Health Care Services

Retrieved on: 
Thursday, February 8, 2024
Health, General Health, Assessment, Personality, Hope, Insurance, Brain, Substance abuse, Depression, FDG-PET, Brain mapping, Dementia, Psychology, Ocean Drive, Anxiety, Function (mathematics), Addiction medicine, MRO, Neuro, Attention, Family, Neuroimaging, Mental health, Deficit spending, Chronic pain, Trauma, Mental, QEEG, Patient, Myenteric plexus, DRS, Medicine, Research, Memory, Life, Doctor of Philosophy, Hospital, Biomarker

Caron Treatment Centers , a nonprofit behavioral healthcare leader for almost 70 years dedicated to treatment, research, prevention and addiction medical education, announces the expansion of its groundbreaking Neurorestorative Health Care services provided at The Keele Medical Center in Delray Beach, Fl.

Key Points: 
  • Caron Treatment Centers , a nonprofit behavioral healthcare leader for almost 70 years dedicated to treatment, research, prevention and addiction medical education, announces the expansion of its groundbreaking Neurorestorative Health Care services provided at The Keele Medical Center in Delray Beach, Fl.
  • “We’re excited to share this expertise more broadly and expand our Neurorestorative Health Care offerings to help more individuals optimize their brain health.”
    Individuals interested in more information about Caron’s 10-day Neurocognitive Assessment or its Neurorestorative Health Care can visit caron.org/neuro-assessment or call 877-369-0109.
  • Caron Treatment Centers is an internationally recognized nonprofit dedicated to addiction and behavioral healthcare treatment, research, prevention, and addiction medicine education.
  • Caron also provides concierge signature treatment for executives, healthcare professionals and older adults and offers Neurorestorative Health Care at our Keele Medical Center in Palm Beach County, Fl.

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors

Retrieved on: 
Thursday, February 8, 2024
Society, International Society, Health, Naltrexone, Knowledge, American Journal, DSM-IV codes, Substance abuse, Opioid use disorder, American College, Addiction medicine, CFO, Addiction, Therapy, GSK plc, American Medical Association, Corcept Therapeutics, OTCQB, Principal investigator, Alzheimer's disease, Neuroscience, Parkinson's disease, Doctor of Philosophy, Merck, Journal, OUD, NACDA, Research, JAMA, Obesity, Anxiety, American Psychiatric Association, Pharmaceutical industry

ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors.

Key Points: 
  • ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors.
  • Dr. DeVarney is the President, Chief Operating Officer, and a Director of Titan Pharmaceuticals, Inc.  She was previously Titan’s Chief Scientific Officer and has been with the company since 2007.
  • Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “We are honored and excited to welcome Dr. DeVarney to the BioCorRx Pharmaceuticals board.
  • I look forward to working closely with the management team to bring BICX104 to market.”

BayCare Expanding Academic Programs to Train West Central Florida's Physicians and Clinicians

Retrieved on: 
Thursday, February 1, 2024
Partnership, Addiction medicine, Psychiatry, Person-centered therapy, Legislature, Emergency medicine, Hospital, ACGME, Accreditation Council, Research, News, Sports medicine, Environment, Child, Patient, Pediatrics, Faculty, Graduate medical education, Nightfall and Other Stories, St. Joseph's Hospital, Physician, Learning, Education, Accreditation, Medicine, Internal medicine, Nursing

The expansion of academic offerings will enhance medical and surgical specialties across the health care system, already the region's provider of choice.

Key Points: 
  • The expansion of academic offerings will enhance medical and surgical specialties across the health care system, already the region's provider of choice.
  • BayCare plans to bring more doctors to West Central Florida by increasing residency positions to more than 650 by 2029.
  • BayCare also has other post-graduate programs supporting pharmacy residents and providing graduate school training for respiratory therapy.
  • Its BayCare Medical Group is the largest multi-specialty practice in the region with 1,120 physicians and advanced practice providers.

NIDA Director to Deliver Keynote; Innovative Toxicology Research to Feature at 2024 ACMT Annual Scientific Meeting and Symposia in Washington, DC

Retrieved on: 
Wednesday, January 17, 2024
AACT, PFAS, Drug Safety, Occupational medicine, Addiction medicine, Research, ASM, Senior counsel, Health, Opioid, Antidote, Challenge, American Academy, Society, IST, Naloxone, Society of Toxicology, Public, Red, Omni Shoreham Hotel, Equity, Nursing, ASAM, Adolescence, American College, Physician

This five-day program will feature the latest advancements in medical toxicology research with numerous opportunities for networking and engagement.

Key Points: 
  • This five-day program will feature the latest advancements in medical toxicology research with numerous opportunities for networking and engagement.
  • Please note that registration for individual symposia is separate from the three-day main meeting.
  • The 2024 ACMT Annual Scientific Meeting main program will initiate on Friday, April 12.
  • Register now for the 2024 ACMT Annual Scientific Meeting and Symposia.

Remote Methadone Dosing Solution Sonara Health Expands into Alaska with SEARHC Partnership

Retrieved on: 
Tuesday, January 23, 2024
Patient, MD, Health, Partnership, Opioid use disorder, Methadone, Addiction medicine, Pharmaceutical industry

JUNEAU, Alaska, Jan. 23, 2024 /PRNewswire/ -- Sonara Health has partnered with SouthEast Alaska Regional Health Consortium to make it easier for patients to access life-saving methadone treatment through Sonara's remote dosing application.

Key Points: 
  • JUNEAU, Alaska, Jan. 23, 2024 /PRNewswire/ -- Sonara Health has partnered with SouthEast Alaska Regional Health Consortium to make it easier for patients to access life-saving methadone treatment through Sonara's remote dosing application.
  • This partnership marks Sonara's first expansion into Alaska, where their solution will be available to eligible patients at clinics in Klawock, Sitka and Juneau.
  • SEARHC provides a wide variety of services to 27 communities in Southeast Alaska, including methadone treatment for Opioid Use Disorder.
  • With Sonara's web-based application, SEARHC patients will be able to record their methadone doses for their care teams to review.